This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic
by Zacks Equity Research
AbbVie, Amgen, Stryker, Dexcom and Medtronic are included in this Analyst Blog.
4 Seniors & Aging Demographics Stocks to Watch Right Now
by Urmimala Biswas
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
Top Analyst Reports for Home Depot, Booking & Eaton
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking Holdings Inc. (BKNG) and Eaton Corporation plc (ETN), as well as a micro-cap stock Value Line, Inc. (VALU).
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
by Kinjel Shah
NVS and ABBV announce small M&A deals. FDA approves the expanded use of PFE and RHHBY's drugs.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Should Pfizer Stock Be in Your Portfolio Post a Robust Q4 Performance?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
The Zacks Analyst Blog Walmart, Visa, AbbVie and AstroNova
by Zacks Equity Research
Walmart, Visa, AbbVie and AstroNova are included in this Analyst Blog.
Earnings Season Scorecard and Fresh Research Reports for Walmart, Visa & AbbVie
by Sheraz Mian
A real-time update on the Q4 earnings season is part of today's Research Daily, in addition to fresh reports on Walmart (WMT), Visa (V), AbbVie (ABBV) and others, including a micro-cap stock AstroNova (ALOT).
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?
by Kinjel Shah
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Company News for Feb 3, 2025
by Zacks Equity Research
Companies in The News Are: ABBV,CVX,ARCB,CHTR
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs
by Zacks Equity Research
ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.
PCE Inflation Increased In Line With Expectation
by Zacks Equity Research
PCE Inflation Increased In Line With Expectation
December PCE Steady with Expectations; Plenty of Mixed Q4 Earnings
by Mark Vickery
PCE results were as in-line with expectations as one could expect: +0.3% on headline month over month, +2.6% year over year.
Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 1.41% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
by Zacks Equity Research
Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT